`
`MADDOX 1r111 EDWARDS
`
`1 900 K STREET NW - SUITE 725
`
`WASHINGTON, DC 20006
`
`(202) 830 - 0707
`
`January 28, 2017
`
`Hon. Paul A. Crotty
`United States District Judge
`Daniel Patrick Moynihan United States Courthouse
`500 Pearl Street, Room 735
`New York, NY 10007
`
`Re:
`
`Kowa Company, Ltd. et al. v. Amneal Pharmaceuticals LLC, et al. ,
`Case Nos. 14-cv-2758 (PAC); 14-cv-7934 (PAC); and 15-cv-3935 (PAC);
`
`Your Honor:
`
`We write in connection with our letter of January 27, 2017, because Plaintiffs since then
`
`have continued to add Sawai documents to Dr. Byrn's list of intended exhibits, despite the facts
`
`that (a) Dr. Byrn has never disclosed any opinions about these documents (Rule 26), (b) Amneal
`
`and Apotex never saw these documents until trial, and (c) Plaintiffs have not offered any
`
`evidentiary foundation for these exhibits. Dr. Byrn is not a rebuttal witness. He is Plaintiffs'
`
`witness for their affirmative case of non-obviousness.
`
`Ninety minutes ago this evening, Plaintiffs identified Sawai Exhibit 74, which would be
`
`in addition to Sawai Exhibit l4B. Neither of these exhibits even appears on Sawai' s exhibit list
`
`submitted with the Pre-Trial Order in this case. Evidently, they were added at an even later date.
`
`Sawai Exhibit 148 is a document predominantly in Japanese, with no translation
`
`provided. We are even now uncertain as to what Sawai Exibit 74 is, except it appears to relate to
`
`some testing done by Sawai - and was the subject of some negotiations exclusively between
`
`Plaintiffs and Sawai.
`
`
`
`Case 1:14-cv-02758-PAC Document 135 Filed 01/28/17 Page 2 of 2
`
`We have filed this letter within hours of Plaintiffs' latest addition, because we believe
`
`these documents should be excluded for the same reasons PTX-735 should be excluded: namely,
`
`failure to have timely identified these documents as the basis for any expert opinion by Dr. Byrn;
`
`Arnneal and Apotex' s lack of access to these documents until trial; and lack (and impossibility
`
`now that Sawai has been dismissed) of any foundation for the admission of these documents.
`
`We hope that our prompt filing will allow Plaintiffs to address all such objectionable testimony
`
`and documents in their letter due by the end of tomorrow.
`
`We maintain that the delay of identification until trial as the basis of undisclosed expert
`
`opinions, and absence of any supplemental report, make Amneal and Apotex's position even
`
`more compelling than Plaintiffs' was with respect to DTX-1442, which the Court excluded.
`
`Finally, Plaintiffs have suggested in conversation that Amneal and Apotex had access to
`
`these documents by virtue of having been in a joint defense group with Sawai and all the other
`
`generic challengers, with whom Amneal and Apotex compete. As you would expect, however,
`
`the Joint Defense Agreement does not give any party rights to documents produced by others,
`
`and does not give any party rights to attend the depositions of others. Amneal and Apotex would
`
`be happy to provide a copy of the Joint Defense Agreement to the Court for in camera review, if
`
`the Court wishes to confirm this fact. We also note that the protective order in each case
`
`prohibits the use of one defendants' document against another without permission.
`
`Respectfully submitted,
`
`cc:
`
`All counsel of record
`
`Steven A. Maddox
`
`